Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 10Sarcoma 3Unspecified Adult Solid Tumor, Protocol Specific 2Neoplasms 2Inflammatory Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Patients With Advanced or Metastatic Solid Tumors 1Ovarian Neoplasms 1Osteosarcoma 1Neutropenia 1Liver Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Bile Duct Neoplasms 1

Interventions

Sorafenib 20Bevacizumab 7pembrolizumab 5Oxaliplatin 5Melphalan 5Leucovorin 5Irinotecan 5Nivolumab 4Ipilimumab 4Fluorouracil 4Cyclophosphamide 4Capecitabine 4fludarabine 3Sirolimus 3Radiosurgery 3Gemcitabine 3Filgrastim 3Carboplatin 3toripalimab 2spartalizumab 2regorafenib 2pazopanib 2lenvatinib 2ixabepilone 2durvalumab 2atezolizumab 2Vorinostat 2Thiotepa 2Temozolomide 2Sirtuins 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Liver Neoplasms × Epirubicin × Clear all
NCT00486356 2024-01-03

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

University of Nebraska

Phase 1 Completed
46 enrolled
Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡